« Return to News | CROs/Service Providers

Variance makes growth investment in Veristat

Friday, January 25, 2013 09:56 AM

Holliston, Mass.-based CRO Veristat said Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms serving developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Veristat has 20 years of expertise supporting clinical trials for pharmaceutical, biotechnology, and medical device companies. Its services include trial design, biostatistics, statistical programming, medical writing, clinical monitoring and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings.

“Many developing CROs are filled with scientific talent which routinely gets distracted from maximizing their client impact by the need to manage their business. Our partnership will allow Veristat to focus its scientific expertise,” said Patrick Flanagan, managing partner with Variance.

Comprised of executives from the pharmaceutical and financial industries, Variance invests in promising companies in the life sciences marketplace to help fuel growth strategies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.